Administration of palivizumab: a medical provider's perspective

Clin Pediatr (Phila). 2003 Nov-Dec;42(9):821-6. doi: 10.1177/000992280304200908.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / economics
  • Cost-Benefit Analysis
  • Humans
  • Infant
  • Infant, Newborn
  • Insurance, Health / economics
  • Insurance, Health / statistics & numerical data
  • Palivizumab
  • Respiratory Syncytial Virus Infections / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • Palivizumab